Literature DB >> 21691126

Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.

E Meijer1, W E Boertien, R Zietse, R T Gansevoort.   

Abstract

The antidiuretic hormone vasopressin is crucial for regulating free water clearance in normal physiology. However, it has also been hypothesized that vasopressin has deleterious effects on the kidney. Vasopressin is elevated in animals and patients with chronic kidney disease. Suppression of vasopressin activity reduces proteinuria, renal hypertrophy, glomerulosclerosis and tubulointerstitial fibrosis in animal models. The potential detrimental influence of vasopressin is probably mediated by its effects on mesangial cell proliferation, renin secretion, renal hemodynamics, and blood pressure. In this review, we discuss the increasing body of evidence pointing towards the contribution of vasopressin to chronic kidney disease progression in general and to autosomal dominant polycystic kidney disease in particular. These data allude to the possibility that interventions directed at lowering vasopressin activity, for example by the administration of vasopressin receptor antagonists or by drinking more water, may be beneficial in chronic kidney disease.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691126     DOI: 10.1159/000326902

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  14 in total

1.  Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Authors:  Ron T Gansevoort; Maatje D A van Gastel; Arlene B Chapman; Jaime D Blais; Frank S Czerwiec; Eiji Higashihara; Jennifer Lee; John Ouyang; Ronald D Perrone; Katrin Stade; Vicente E Torres; Olivier Devuyst
Journal:  Kidney Int       Date:  2019-03-09       Impact factor: 10.612

2.  Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD.

Authors:  Lise Bankir; Daniel G Bichet
Journal:  Nat Rev Nephrol       Date:  2012-06-26       Impact factor: 28.314

3.  Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).

Authors:  W E Boertien; I J Riphagen; I Drion; A Alkhalaf; S J L Bakker; K H Groenier; J Struck; P E de Jong; H J G Bilo; N Kleefstra; R T Gansevoort
Journal:  Diabetologia       Date:  2013-04-28       Impact factor: 10.122

4.  Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects.

Authors:  Susan E Shoaf; Suresh Mallikaarjun; Patricia Bricmont
Journal:  Eur J Clin Pharmacol       Date:  2011-08-19       Impact factor: 2.953

5.  Conivaptan and Boric Acid Treatments in Acute Kidney Injury: Is This Combination Effective and Safe?

Authors:  Betül Can; Fatih Kar; Ezgi Kar; Mete Özkoç; Hakan Şentürk; Dilek Burukoğlu Dönmez; Güngör Kanbak; İbrahim Özkan Alataş
Journal:  Biol Trace Elem Res       Date:  2021-10-21       Impact factor: 3.738

Review 6.  Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Authors:  Markus M Rinschen; Bernhard Schermer; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

7.  Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Authors:  Debbie Zittema; Else van den Berg; Esther Meijer; Wendy E Boertien; Anneke C Muller Kobold; Casper F M Franssen; Paul E de Jong; Stephan J L Bakker; Gerjan Navis; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

8.  The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial.

Authors:  Judith E Heida; Ron T Gansevoort; Vicente E Torres; Olivier Devuyst; Ronald D Perrone; Jennifer Lee; Hui Li; John Ouyang; Arlene B Chapman
Journal:  J Am Soc Nephrol       Date:  2021-04-22       Impact factor: 14.978

9.  Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease.

Authors:  Ismail Kocyigit; Mahmut Ilker Yilmaz; Ozkan Gungor; Eray Eroglu; Aydin Unal; Ozcan Orscelik; Bulent Tokgoz; Murat Sipahioglu; Ahmet Sen; Juan Jesús Carrero; Oktay Oymak; Jonas Axelsson
Journal:  BMC Nephrol       Date:  2016-11-30       Impact factor: 2.388

10.  Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?

Authors:  Eiji Higashihara; Kikuo Nutahara; Mitsuhiro Tanbo; Hidehiko Hara; Isao Miyazaki; Kuninori Kobayashi; Toshiaki Nitatori
Journal:  Nephrol Dial Transplant       Date:  2014-04-15       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.